SCHEMBL3767827

SCHEMBL3767827

O=C(Nc1ccc(Nc2ncnc3[nH]ccc(=O)c23)cc1)Nc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 2/20 0.50
▸ RIPK1 Q13546 2/20 0.49
▸ KIT P10721 5/20 0.48
▸ KDR P35968 10/20 0.47
▸ FLT3 P36888 4/20 0.47
▸ NTRK1 P04629 2/20 0.47
▸ NTRK3 Q16288 1/20 0.47
▸ NTRK2 Q16620 1/20 0.47
▸ IKBKE Q14164 1/20 0.47
▸ TOP2B Q02880 1/20 0.46
▸ RET P07949 1/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ CSF1R P07333 1/20 0.44
▸ LYN P07948 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ FLT1 P17948 1/20 0.44
▸ FLT4 P35916 1/20 0.44
▸ BLK P51451 1/20 0.44
▸ MET P08581 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762266 0.89 KIT (0.62) CDK8RIPK1KITKDRFLT3
SCHEMBL3763784 0.87 KDR (0.47) CDK8KITKDRNTRK1NTRK3
SCHEMBL3761347 0.86 CA12 (0.52) CDK8RIPK1KITKDRFLT3
SCHEMBL3762938 0.84 RET (0.60) CDK8RIPK1KITKDRFLT3
SCHEMBL3763767 0.83 NTRK1 (0.51) RIPK1KDRFLT3NTRK1NTRK3
SCHEMBL3763732 0.82 NTRK1 (0.43) CDK8KITKDRFLT3NTRK1
SCHEMBL3767943 0.80 FLT3 (0.53) CDK8KDRFLT3NTRK1NTRK3
SCHEMBL9903598 0.79 BRAF (0.52) KDRNTRK1NTRK3NTRK2ABL1
SCHEMBL3765192 0.79 KDR (0.56) CDK8KITKDRNTRK1NTRK3
SCHEMBL9903084 0.78 BRAF (0.58) KDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809629-B1 N,N'-diphenyl urea derivatives suitable for the treatment of tumours, eye diseases, inflammation and diseases of the immune system MERCK PATENT GMBH (DE) 2012-06-13 — — EP claimed
US-7846927-B2 N,N′-diphenylurea derivatives suitable as kinase inhibitors MERCK PATENT GMBH (DE) 2010-12-07 — — US claimed
US-20070293488-A1 tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis MERCK PATENT GMBH (DE) 2007-12-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293488-A1 tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis TIE1, FLT1, FER CDK8 152/4885RIPK1 235/4885KIT 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback